We focus on “hard targets” in cancer and autoimmune disease with strong biological validation that have not been successfully drugged
We deploy our proprietary Rational Antibody Discovery platform to discover and engineer precision therapies, unlocking the therapeutic potential of these targets
Pipeline & Partners
Hummingbird Bioscience Announces UK MHRA Approval for First-in-Human Phase 1 Trial of...
02 August 2021
Hummingbird Bioscience Appoints Renowned Scientist and Medical Oncologist Dr. Thomas J. Lynch...
26 July 2021